25I-NB3OMe (2C-I-NB3OMe, NB3OMe-2C-I) is a phenethylamine hallucinogen which acts as a partial agonist for the human 5-HT2A receptor.[1] It is a derivative of 2C-I.

25I-NB3OMe
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(3-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H22INO3
Molar mass427.282 g·mol−1
3D model (JSmol)
  • COC1=CC=CC(=C1)CNCCC2=CC(=C(C=C2OC)I)OC
  • InChI=1S/C18H22INO3/c1-21-15-6-4-5-13(9-15)12-20-8-7-14-10-18(23-3)16(19)11-17(14)22-2/h4-6,9-11,20H,7-8,12H2,1-3H3
  • Key:CJTZKPLDKCBUAF-UHFFFAOYSA-N

Legality

edit

United Kingdom

edit

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[2]

United States

edit

25I-NB3OMe is not explicitly listed as a controlled substance in the United States, but is a positional isomer of 25I-NBOMe[3] and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.

References

edit
  1. ^ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
  2. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.
  3. ^ Casale JF, Hays PA (2012). "Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I". Microgram Journal. 9 (2): 84–109.